

WEST PHARMACEUTICAL SERVICES INC  
Form 8-K  
June 14, 2005

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

---

#### CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) June 8, 2005

---

### WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

---

**Pennsylvania**  
(State or other jurisdiction  
of incorporation)

**1-8036**  
(Commission File Number)

**23-1210010**  
(IRS Employer  
Identification No.)

**101 Gordon Drive, PO Box 645, Lionville, PA**  
(Address of principal executive offices)

**19341-0645**  
(Zip Code)

**610-594-2900**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On June 8, 2005, West Pharmaceutical Services, Inc. (the Company) entered into a long-term supply contract with Goodyear Tire & Rubber Company. Under the contract, Goodyear will supply a majority of the Company's worldwide requirements of polyisoprene and styrene-butadiene rubber, a key raw material in the Company's disposable medical device products. The contract contains fixed pricing at current market rates with adjustments based on raw materials indices, as well as indemnification of the vendor against certain product-related claims. The contract, which became effective as of January 1, 2005, will continue until December 31, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III  
John R. Gailey III  
Vice President, General Counsel

June 14, 2005